Clinical Trials Logo

Opioid-use Disorder clinical trials

View clinical trials related to Opioid-use Disorder.

Filter by:

NCT ID: NCT04365465 Completed - Pain, Postoperative Clinical Trials

BRIDGE Percutaneous Nerve Stimulation for Cesarean Delivery Pain Control

Start date: August 17, 2020
Phase: N/A
Study type: Interventional

This is a randomized, placebo controlled and natural-history controlled trial to investigate the effectiveness of NSS-2 BRIDGE® for postpartum women with AND without opioid use disorder (OUD). The purpose of this pilot investigation is to establish feasibility/acceptability of the trial design.

NCT ID: NCT04363320 Completed - Opioid-use Disorder Clinical Trials

Fostering MAT Use in Justice Populations

Start date: July 30, 2020
Phase: N/A
Study type: Interventional

The grant will test two timely and successful evidence-based implementation practices, NIATx Coaching and ECHO, with jail/community-based healthcare providers to increase medication assisted treatment (MAT) use with justice populations.

NCT ID: NCT04340622 Completed - Opioid-use Disorder Clinical Trials

Efficacy And Safety Of An Innovative Treatment Of Opiate Use Disorders

Start date: November 12, 2019
Phase: N/A
Study type: Interventional

Investigators will test, for safety and efficacy, a novel treatment for opiate addiction that applies a 4-minute treatment of intense near infra-red light to stimulate a side of the brain that the investigators determine to be healthier, more mature, and less traumatized. Investigators will compare an active and a sham treatment given twice weekly for 4-weeks. Investigators hope this will lead to a significant weapon in the battle against the opioid epidemic as well as lead to psychological and physiological insights into possible relations among trauma, cerebral laterality, and addiction.

NCT ID: NCT04314648 Completed - Clinical trials for Alcohol Use Disorder

Substance Use Treatment and Recovery Team (START)

START
Start date: December 4, 2020
Phase: N/A
Study type: Interventional

Despite high prevalence, few hospitalized inpatients with opioid or alcohol use disorders (OAUDs) receive evidence-based treatments while in the hospital or get linked with appropriate follow-up care, leading to poor clinical outcomes and high readmission rates and costs. The purpose of this study is to evaluate whether a physician and care manager with addiction expertise, both members of the Substance Abuse Treatment and Recovery Team (START), can help improve initiation of treatment in the hospital and linkage to follow-up care upon discharge. START members have expertise in the treatment of substance use disorders. START will work with the medical or surgical team to ensure appropriate care is received. That care will include therapy, focused discharge planning, and medication treatment options. START will also help establish a follow-up plan for continuation of treatment after hospital discharge. To assess feasibility, the study will enroll 80 patients admitted to the hospital over 5 months in a pilot randomized clinical trial and collect baseline and 1-month follow-up data. To determine acceptability, the study will conduct semi-structured interviews with 40 providers. Results of this pilot study will inform a larger clinical trial.

NCT ID: NCT04314414 Completed - HIV Infections Clinical Trials

Coaching for HCV and HIV

Start date: December 20, 2020
Phase: N/A
Study type: Interventional

The objective of this study is to determine the feasibility and acceptability of a peer recovery coach (PRC) intervention to improve linkage to hepatitis C (HCV) and/or human immunodeficiency virus (HIV) care, treatment initiation, and evaluation for HIV pre-exposure prophylaxis (PrEP) (when applicable) among individuals with a history of opioid use disorder accessing a substance use low-barrier-to-access (LBA) walk-in clinic. In-depth interviews will be administered to participants at baseline, three- and six-months for study participants (40 total participants). The investigator will also follow-up with the per recovery coach and administer surveys to assess the feasibility of a peer recovery coaching intervention in improving HCV/HIV related linkage to care and management. Patient medical records and peer recovery coach monthly reports will be accessed and reviewed to determine fidelity to research protocols.

NCT ID: NCT04308694 Completed - Opioid-use Disorder Clinical Trials

Opioid Treatment Program (OTP)-Pharmacy Collaboration for Methadone Maintenance Treatment

Start date: August 6, 2020
Phase: Early Phase 1
Study type: Interventional

The overarching goal of this pilot study is to explore the feasibility, acceptability, and patient/provider satisfaction of pharmacy-based administration and dispensing of methadone for opioid use disorder. The results gained will inform the development of a future multisite randomized clinical trial.

NCT ID: NCT04308655 Completed - Opioid-use Disorder Clinical Trials

Obstetric Pain Management for Women With Opioid Use Disorder (QUEST)

QUEST
Start date: March 6, 2020
Phase:
Study type: Observational

This is a mixed methods longitudinal observational study to assess patient and provider perspectives on pain and pain management among pregnant women with opiate use disorder (OUD). The findings from this study will inform patient-centered approaches to pain management. Themes surrounding mothers' pain/recovery experiences that correlate with quantified pain and analgesia endpoints will be identified. Findings will also shape an appropriate patient-centered research agenda for obstetric pain management in patients with OUD.

NCT ID: NCT04289363 Completed - Opioid-use Disorder Clinical Trials

Emergency Department Outcomes for Patients With Opioid Use Disorder

Start date: November 25, 2020
Phase:
Study type: Observational

Using mixed methods and triangulating multiples sources of data collected over the course of the parent (CTN-0079 - NCT03544112) and the ancillary studies to evaluate the feasibility, acceptability, sustainability and impact of the emergency department (ED)-initiated Buprenorphine (BUP) clinical program and implementation facilitation strategy and identify factors influencing diffusion and effectiveness.

NCT ID: NCT04283500 Completed - Opioid-use Disorder Clinical Trials

Buprenorphine Loading in the Emergency Department

Start date: November 1, 2020
Phase: Phase 4
Study type: Interventional

Buprenorphine (BUP) is FDA-approved for the treatment of opioid withdrawal and opioid use disorder. Few ED providers have received the necessary DEA registration (aka X waiver) required to prescribe BUP, and urgent appointments to continue ongoing BUP treatment may not be readily available, thus leading to medication discontinuity. A loading dose induction strategy with 32mg of BUP may help effectively link ED patients to outpatient treatment while minimizing known barriers to ED uptake. Administering a "loading dose" of BUP to saturate mu-opioid receptors would extend the duration of action and provide additional time to secure ongoing treatment. Further, BUP's ceiling effect on respiratory depression makes it a remarkably safe drug even at high doses. In recent years, ED providers have begun to incorporate this approach into clinical protocols, however, it has not been formally studied in this clinical setting. The investigator's study represents the necessary step of studying this novel approach in the ED setting to define the parameters for clinical protocols and large-scale studies.

NCT ID: NCT04278586 Completed - Depression Clinical Trials

Effect of Mindfulness on Opioid Use and Anxiety During Primary Care Buprenorphine Treatment (R33 Phase)

Mindful-OBOT
Start date: February 15, 2021
Phase: N/A
Study type: Interventional

This will be a randomized controlled trial (RCT) designed to compare live-online Mindful Recovery Opioid Care Continuum (M-ROCC) groups with a live-online control group on the primary outcome of number of biochemically confirmed opioid negative abstinent periods (defined by a negative oral fluid test [negative for opiate, oxycodone, fentanyl, methadone] AND no self-reported illicit opioid use) during the final six two-week periods of the study (study weeks 13-24).